Valeant Pharmaceuticals International Provides Earnings Guidance for the Year 2015 and 2016
For 2016 the company is targeting full year revenue of $12.5 billion to $12.7 billion and adjusted EPS of $13.25 to $13.75 a share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.79 USD | -0.15% | +4.95% | -15.34% |
1st Jan change | Capi. | |
---|---|---|
-15.34% | 2.49B | |
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |